Navigation Links
Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents
Date:10/21/2010

CAMBRIDGE, Mass., Oct. 21 /PRNewswire/ -- Sermo (http://www.sermo.com), the largest online community for physicians, today announced a free Sermo Report titled, "Physician Participation in the ESA REMS Program." The report covers physician perceptions and participation rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation and mitigation strategy (REMS) program.

According to the results, 83% of Hematologists/Oncologists view the ESA REMS program as a barrier to utilization of associated drugs. As one HemOnc noted, "The purpose of REMS is to reduce patient access to ESAs, or more accurately to reduce their demand by scaring them away, and also by limiting the supply of physicians who are willing to put up with the work for little return."

This free Sermo Report polled 60 physicians who also participated in an online discussion regarding treatment strategies for renal associated anemia.

Highlights from the report include:

  • Physicians are not aware of how to participate in the REMS program. If they have participated, it was most likely required by their place of employment. "Gov't said I had to," said a HemOnc respondent. "Nice way to pass the buck of blame to doctors."
  • REMS programs are perceived by physicians as more work, and reduced access for the patient. According to a HemOnc respondent, "REMS programs simply transform pharma liability risk into more work for physicians… I would rather not even prescribe a drug than generate more busywork for me or my staff. So this reduced prescribing of a REMS drug translates into reduced access for the patient."

The full reports includes:

  • Key Findings
  • Physician Demographics
  • Quantitative and Qualitative Analysis

Physicians are required to complete the ESA REMS program by March 2011 to be eligible to prescribe these products. The goals of the REMS for ESAs are:

  • To support informed decisions between patients, their physicians, and other healthcare professionals by educating them on the risks of ESAs.
  • To mitigate the risk of decreased survival and/or poorer tumor outcomes in patients with cancer by implementing the part of the REMS called the ESA APPRISE Oncology Program.

Erythropoiesis Stimulating Agents include products from Amgen and Centocor Ortho Biotech Products, L.P.

To download report results, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, and trends. Data for Sermo Reports is gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic.  All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 115,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For information, visit www.sermo.com/clients.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sermo Announces New Client Center with Advanced Mining and Monitoring of Organic Physician Dialog
2. All-New Sermo Brings Major Enhancements to Nations Largest Online Physician Community
3. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
4. China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
5. Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
6. Reportlinker Adds BioMEMS 2010
7. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
8. Reportlinker Adds Breast Cancer Drug Futures
9. Reportlinker Adds Industrial Biotechnology China News 1009
10. In-demand Contemporary Research Reports on Biotechnology Markets Available at MCGroup.co.uk
11. Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):